Abstract β-Adrenergic receptor blockers (β-blockers) are well-known useful and cost-
effective drugs for managing hypertensive patients with coronary heart disease, stroke, and …

Nebivolol, a selective β1-lipophilic blocker, achieves blood pressure control by modulating
nitric oxide release in addition to b-blockade. This dual mechanism of action could result in …

Although the regulation of arterial blood flow has been a subject of intensive medical
research, the precise circulatory mechanisms involved are still not fully understood. It has …

Nebivolol is a selective [beta] 1-adrenoceptor antagonist with a particular hemodynamic
profile, suggesting an ancillary vasodilating property. The nature of this ancillary property is …

The cardiovascular effects and pharmacokinetics of nebivolol were assessed in N (G)-nitro-l-
arginine methyl ester (L-NAME) hypertensive and normotensive control rats. Male Wistar …

We aim to determine whether nebivolol has a better effect on endothelial dysfunction
compared with other β-blockers or other classes of antihypertensive drugs. Searches of the …

Background Nebivolol is a novel, β1‐adrenergic receptor blocker with vasodilatory
properties mediated through activation of the L‐arginine/nitric oxide pathway. Hypothesis …

BACKGROUND: Sildenafil citrate (SIL) is contraindicated in patients with coronary heart
disease who are treated with nitric oxide (NO) donators such as organic nitrates, as it …

Nebivolol, a third generation selective β1-adrenoceptor (β1-AR) antagonist, has been
reported to reduce intracellular oxidative stress and to induce the release of nitric oxide (NO) …

Nebivolol and metoprolol are β 1-adrenergic receptor blockers with different properties. We
hypothesized that nebivolol, but not metoprolol, could attenuate prooxidant and profibrotic …